In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses

Antiviral Research

Volumn 84, Issue 3, 2009, Pages 234-241

  Kampmann, Thorsten ^a   Yennamalli, Ragothaman ^a,b   Campbell, Phillipa ^a   Stoermer, Martin J ^a   Fairlie, David P ^a   Kobe, Bostjan ^a   Young, Paul R ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

Antiviral; Dengue virus; Flavivirus; Fusion inhibition; Virtual screening

Indexed keywords

ANTIVIRUS AGENT; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS ENVELOPE PROTEIN E;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; COMPUTER ANALYSIS; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DATA BASE; DENGUE VIRUS; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; FLAVIVIRUS; IC 50; LIGAND BINDING; MEMBRANE FUSION; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; VERO CELL; WEST NILE FLAVIVIRUS; YELLOW FEVER FLAVIVIRUS;

ANIMALS; ANTIVIRAL AGENTS; BINDING SITES; CERCOPITHECUS AETHIOPS; DENGUE VIRUS; DRUG EVALUATION, PRECLINICAL; FLAVIVIRUS; FLAVIVIRUS INFECTIONS; HUMANS; PROTEIN BINDING; SMALL MOLECULE LIBRARIES; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

DENGUE VIRUS; DENGUE VIRUS GROUP; FLAVIVIRUS; WEST NILE VIRUS; YELLOW FEVER VIRUS;

EID: 70449522054     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.09.007     Document Type: Article

References (50)

1. Adelman Z.N., Sanchez-Vargas I., Travanty E.A., Carlson J.O., Beaty B.J., Blair C.D., and Olson K.E. RNA silencing of dengue virus type 2 replication in transformed C6/36 mosquito cells transcribing an inverted-repeat RNA derived from the virus genome. J. Virol. 76 (2002) 12925-12933
2. Allison S.L., Schalich J., Stiasny K., Mandl C.W., Kunz C., and Heinz F.X. Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH. J. Virol. 69 (1995) 695-700
3. Anderson R., King A.D., and Innis B.L. Correlation of E protein binding with cell susceptibility to dengue 4 virus infection. J. Gen. Virol. 73 (1992) 2155-2159
4. Bai F., Town T., Pradhan D., Cox J., Ashish, Ledizet M., Anderson J.F., Flavell R.A., Krueger J.K., Koski R.A., and Fikrig E. Antiviral peptides targeting the West Nile virus envelope protein. J. Virol. 81 (2007) 2047-2055
5. Bai F., Wang T., Pal U., Bao F., Gould L.H., and Fikrig E. Use of RNA interference to prevent lethal murine West Nile virus infection. J. Infect. Dis. 191 (2005) 1148-1154
6. Brandriss M.W., Schlesinger J.J., Walsh E.E., and Briselli M. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J. Gen. Virol. 67 (1986) 229-234
7. Bressanelli S., Stiasny K., Allison S.L., Stura E.A., Duquerroy S., Lescar J., Heinz F.X., and Rey F.A. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J. 23 (2004) 728-738
8. Chu J.J., and Yang P.L. c-Src protein kinase inhibitors block assembly and maturation of dengue virus. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 3520-3525
9. Coia G., Parker M.D., Speight G., Byrne M.E., and Westaway E.G. Nucleotide and complete amino acid sequences of Kunjin virus: definitive gene order and characteristics of the virus-specified proteins. J. Gen. Virol. 69 (1988) 1-21
10. Courageot M.P., Frenkiel M.P., Dos Santos C.D., Deubel V., and Desprès P. Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J. Virol. 74 (2000) 564-572
11. Fritz R., Stiasny K., and Heinz F.X. Identification of specific histidines as pH sensors in flavivirus membrane fusion. J. Cell. Biol. 183 (2008) 353-361
12. Gruenberg A., Woo W.S., Biedrzycka A., and Wright P.J. Partial nucleotide sequence and deduced amino acid sequence of the structural proteins of dengue virus type 2 New Guinea C and PUO-218 strains. J. Gen. Virol. 69 (1988) 1391-1398
13. Guirakhoo F., Heinz F.X., Mandl C.W., Holzmann H., and Kunz C. Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions. J. Gen. Virol. 72 (1991) 1323-1329
14. Hahn C.S., Dalrymple J.M., Strauss J.H., and Rice C.M. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 2019-2023
15. Hall R.A., Scherret J.H., and Mackenzie J.S. Kunjin virus: an Australian variant of West Nile?. Ann. N.Y. Acad. Sci. 951 (2001) 153-160
16. Heinz F.X., and Allison S.L. The machinery for flavivirus fusion with host cell membranes. Curr. Opin. Microbiol. 4 (2001) 450-455
17. Hrobowski Y.M., Garry R.F., and Michael S.F. Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol. J. 2 (2005) 49
18. Hurrelbrink R.J., and McMinn P.C. Attenuation of Murray Valley encephalitis virus by site-directed mutagenesis of the hinge and putative receptor-binding regions of the envelope protein. J. Virol. 75 (2001) 7692-7702
19. Jacobs M.G., and Young P.R. Dengue: a continuing challenge for molecular biology. Curr. Opin. Infect. Dis. 11 (1998) 319-324
20. Kampmann T., Mueller D.S., Mark A.E., Young P.R., and Kobe B. The role of histidine residues in low-pH-mediated viral membrane fusion. Structure 14 (2006) 1481-1487
21. Kanai R., Kar K., Anthony K., Gould L.H., Ledizet M., Fikrig E., Marasco W.A., Koski R.A., and Modis Y. Crystal structure of West Nile virus envelope glycoprotein reveals viral surface epitopes. J. Virol. 80 (2006) 11000-11008
22. Kimura-Kuroda J., and Yasui K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J. Immunol. 141 (1988) 3606-3610
23. Knox J.E., Ma N.L., Yin Z., Patel S.J., Wang W.L., Chan W.L., Ranga Rao K.R., Wang G., Ngew X., Patel V., Beer D., Lim S.P., Vasudevan S.G., and Keller T.H. Peptide inhibitors of West Nile NS3 protease: SAR study of tetrapeptide aldehyde inhibitors. J. Med. Chem. 49 (2006) 6585-6590
24. Lanciotti R.S., Roehrig J.T., Deubel V., Smith J., Parker M., Steele K., Crise B., Volpe K.E., Crabtree M.B., Scherret J.H., Hall R.A., MacKenzie J.S., Cropp C.B., Panigrahy B., Ostlund E., Schmitt B., Malkinson M., Banet C., Weissman J., Komar N., Savage H.M., Stone W., McNamara T., and Gubler D.J. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 286 (1999) 2333-2337
25. Lee E., Weir R.C., and Dalgarno L. Changes in the dengue virus major envelope protein on passaging and their localization on the three-dimensional structure of the protein. Virology 232 (1997) 281-290
26. Leung D., Schroder K., White H., Fang N.X., Stoermer M.J., Abbenante G., Martin J.L., Young P.R., and Fairlie D.P. Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J. Biol. Chem. 276 (2001) 45762-45771
27. Li Z., Khaliq M., Zhou Z., Post C.B., Kuhn R.J., and Cushman M. Design, synthesis, and biological evaluation of antiviral agents targeting flavivirus envelope proteins. J. Med. Chem. 51 (2008) 4660-4671
28. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3-25
29. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001) 3-26
30. Marks R.M., Lu H., Sundaresan R., Toida T., Suzuki A., Imanari T., Hernaiz M.J., and Linhardt R.J. Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors. J. Med. Chem. 44 (2001) 2178-2187
31. Mathews J.H., and Roehrig J.T. Elucidation of the topography and determination of the protective epitopes on the E glycoprotein of Saint Louis encephalitis virus by passive transfer with monoclonal antibodies. J. Immunol. 132 (1984) 1533-1537
32. McCown M., Diamond M.S., and Pekosz A. The utility of siRNA transcripts produced by RNA polymerase I in down regulating viral gene expression and replication of negative- and positive-strand RNA viruses. Virology 313 (2003) 514-524
33. Modis Y., Ogata S., Clements D., and Harrison S.C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 6986-6991
34. Modis Y., Ogata S., Clements D., and Harrison S.C. Structure of the dengue virus envelope protein after membrane fusion. Nature 427 (2004) 313-319
35. Monath T.P. Treatment of yellow fever. Antiviral Res. 78 (2008) 116-124
36. Monath T.P., Arroyo J., Levenbook I., Zhang Z.X., Catalan J., Draper K., and Guirakhoo F. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J. Virol. 76 (2002) 1932-1943
37. Morrey J.D., Smee D.F., Sidwell R.W., and Tseng C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res. 55 (2002) 107-116
38. Nybakken G.E., Nelson C.A., Chen B.R., Diamond M.S., and Fremont D.H. Crystal structure of the West Nile virus envelope glycoprotein. J. Virol. 80 (2006) 11467-11474
39. Puig-Basagoiti F., Tilgner M., Forshey B.M., Philpott S.M., Espina N.G., Wentworth D.E., Goebel S.J., Masters P.S., Falgout B., Ren P., Ferguson D.M., and Shi P.Y. Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob. Agents Chemother. 50 (2006) 1320-1329
40. Randolph V.B., and Stollar V. Low pH-induced cell fusion in flavivirus-infected Aedes albopictus cell cultures. J. Gen. Virol. 71 (1990) 1845-1850
41. Rey F.A., Heinz F.X., Mandl C., Kunz C., and Harrison S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2A resolution. Nature 375 (1995) 291-298
42. Shimoni Z., Niven M.J., Pitlick S., and Bulvik S. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg. Infect. Dis. 7 (2001) 759
43. Verdonk M.L., Cole J.C., Hartshorn M.J., Murray C.W., and Taylor R.D. Improved protein-ligand docking using GOLD. Proteins 52 (2003) 609-623
44. Whitby K., Pierson T.C., Geiss B., Lane K., Engle M., Zhou Y., Doms R.W., and Diamond M.S. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J. Virol. 79 (2005) 8698-8706
45. Wu S.F., Lee C.J., Liao C.L., Dwek R.A., Zitzmann N., and Lin Y.L. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 76 (2002) 3596-3604
46. Yang J.M., Chen Y.F., Tu Y.Y., Yen K.R., and Yang Y.L. Combinatorial computational approaches to identify tetracycline derivatives as flavivirus inhibitors. PLoS ONE 2 (2007) e428
47. Yennamalli R., Subbarao N., Kampmann T., McGeary R.P., Young P.R., and Kobe B. Identification of novel target sites and an inhibitor of the dengue virus E protein. J. Comput. Aided Mol. Des. 23 (2009) 333-341
48. Zhang N., Chen H.M., Koch V., Schmitz H., Minczuk M., Stepien P., Fattom A.I., Naso R.B., Kalicharran K., Borowski P., and Hosmane R.S. Potent inhibition of NTPase/helicase of the West Nile Virus by ring-expanded ("fat") nucleoside analogues. J. Med. Chem. 46 (2003) 4776-4789
49. Zhang Y., Zhang W., Ogata S., Clements D., Strauss J.H., Baker T.S., Kuhn R.J., and Rossmann M.G. Conformational changes of the flavivirus E glycoprotein. Structure 12 (2004) 1607-1618
50. Zhou Z., Khaliq M., Suk J.E., Patkar C., Li L., Kuhn R.J., and Post C.B. Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein. ACS Chem. Biol. 3 (2008) 765-775